UnknownNot Applicable

Role of Fenofibrate in Indirect Neonatal Hyperbilirubinemia: a Randomized Control Trial

60 participantsStarted 2021-09

Plain-language summary

Fenofibrate accelerates bilirubin conjugation and excretion, decreasing the side effects of prolonged unconjugated hyperbilirubinemia in neonates. It also reduces the duration of phototherapy and thus the duration of stay in the hospital. This research is carried out to improve standard protocol for the management of neonatal hyperbilirubinemia in the local settings.

Who can participate

Age range2 Days – 7 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

INCLUSION CRITERIA: * Gestational age ≥ 35 weeks * Birth weight ≥ 2 kg * Age: 2-7 days of life * Total serum bilirubin level ≥15mg/dl and ≤20 mg/dl EXCLUSION CRITERIA: * Neonates with total bilirubin \>20mg/dl * Conjugated bilirubin level greater than 15% of total serum bilirubin * Maternal hyperbilirubinemia (on medical record) * Babies with congenital anomalies (on clinical examination) * Those not consenting to participate in the study

What they're measuring

Duration of phototherapy

Timeframe: 6 months

Trial details

NCT IDNCT04868019

SponsorShaheed Zulfiqar Ali Bhutto Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-02

View on ClinicalTrials.gov More Hyperbilirubinemia, Neonatal trials